Cargando…
New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema
We evaluated the long-term (24-month) efficacy of a novel individualized treatment protocol with 2 mg aflibercept for treatment-naive BRVO with macular edema. Each patient received an initial aflibercept injection and was then examined every 2 weeks until recurrence of edema. At recurrence, each pat...
Autores principales: | Noma, Hidetaka, Yasuda, Kanako, Narimatsu, Akitomo, Asakage, Masaki, Shimura, Masahiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883511/ https://www.ncbi.nlm.nih.gov/pubmed/36707696 http://dx.doi.org/10.1038/s41598-023-28533-z |
Ejemplares similares
-
Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
por: Otawa, Taro, et al.
Publicado: (2022) -
Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2019) -
Effects of Intravitreal Ranibizumab Injection to Treat Macular Edema due to Central Retinal Vein Occlusion on Choroidal Findings and Functional-Morphological Parameters
por: Yasuda, Kanako, et al.
Publicado: (2023) -
Retinal Microcirculation and Cytokines as Predictors for Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2020) -
Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema
por: Yasuda, Kanako, et al.
Publicado: (2023)